Pfizer Inc. (NYSE:PFE) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

"Our revenue volatility is largely in the past as COVID-related uncertainties have diminished," Pfizer's finance chief David ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Eligible Medicare beneficiaries can access Paxlovid at no cost until February 28, 2025, through a patient assistance program operated by the manufacturer, Pfizer. This initiative ensures that ...

U.S. health experts anticipate a smaller wave of COVID-19 cases this winter, potentially impacting Pfizer's non-COVID ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...